Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.

BACKGROUND Imatinib (400 mg daily) is considered the best initial therapy for patients with newly diagnosed chronic myeloid leukemia (CML) in the chronic phase. However, only a minority of patients treated with imatinib have a complete molecular remission. METHODS We randomly assigned 636 patients with untreated chronic-phase CML to receive imatinib alone at a dose of 400 mg daily, imatinib (400 mg daily) plus cytarabine (20 mg per square meter of body-surface area per day on days 15 through 28 of each 28-day cycle) or pegylated interferon (peginterferon) alfa-2a (90 μg weekly), or imatinib alone at a dose of 600 mg daily. Molecular and cytogenetic responses, time to treatment failure, overall and event-free survival, and adverse events were assessed. An analysis of molecular response at 12 months was planned. A superior molecular response was defined as a decrease in the ratio of transcripts of the tyrosine kinase gene BCR-ABL to transcripts of ABL of 0.01% or less, corresponding to a reduction of 4 log(10) units or more from the baseline level, as assessed by means of a real-time quantitative polymerase-chain-reaction assay. RESULTS At 12 months, the rates of cytogenetic response were similar among the four groups. The rate of a superior molecular response was significantly higher among patients receiving imatinib and peginterferon alfa-2a (30%) than among patients receiving 400 mg of imatinib alone (14%) (P=0.001). The rate was significantly higher among patients treated for more than 12 months than among those treated for 12 months or less. Gastrointestinal events were more frequent among patients receiving cytarabine, whereas rash and depression were more frequent among patients receiving peginterferon alfa-2a. CONCLUSIONS As compared with other treatments, the addition of peginterferon alfa-2a to imatinib therapy resulted in significantly higher rates of molecular response in patients with chronic-phase CML. (Funded by the French Ministry of Health and others; ClinicalTrials.gov number, NCT00219739.).

[1]  M. Tulliez,et al.  Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase. , 2003, Blood.

[2]  Francisco Cervantes,et al.  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. , 2003, The New England journal of medicine.

[3]  J. Cayuela,et al.  Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. , 2005, Blood.

[4]  M. Copland,et al.  Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. , 2006, Blood.

[5]  G. Canellos,et al.  Chronic granulocytic leukemia. , 1976, The Medical clinics of North America.

[6]  Francisco Cervantes,et al.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.

[7]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[8]  H. Cavé,et al.  Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program , 2003, Leukemia.

[9]  M. Gordon.  Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia , 2010 .

[10]  E. McFadden,et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.

[11]  J. Lipton,et al.  Phase II, randomized, multicenter, comparative study of peginterferon-alpha-2a (40 kD) (Pegasys) versus interferon alpha-2a (Roferon-A) in patients with treatment-naïve, chronic-phase chronic myelogenous leukemia. , 2007, Leukemia & lymphoma.

[12]  T. Holyoake,et al.  Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. , 2007, Blood.

[13]  J. Radich,et al.  Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia , 2010, Leukemia.

[14]  M. Gordon.  Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia , 2010 .

[15]  Yukio Kondo,et al.  TGF-β–FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia , 2010, Nature.

[16]  Andreas Trumpp,et al.  IFNα activates dormant haematopoietic stem cells in vivo , 2009, Nature.

[17]  M. Gasparetto,et al.  Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies , 2007, Leukemia.

[18]  Ricardo Pasquini,et al.  Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. , 2010, The New England journal of medicine.

[19]  M. Dolgin,et al.  Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels , 1994 .

[20]  J. Rowley.  A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining , 1973, Nature.

[21]  P. Nowell,et al.  A minute chromosome in human chronic granulocytic leukemia , 1960 .

[22]  E. Canaani,et al.  Fused transcript of abl and bcr genes in chronic myelogenous leukaemia , 1985, Nature.

[23]  R. Silver,et al.  Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study , 2004, Leukemia.

[24]  N. Cross,et al.  Harmonization of molecular monitoring of CML therapy in Europe , 2009, Leukemia.

[25]  Francisco Cervantes,et al.  Prognostic discrimination in "good-risk" chronic granulocytic leukemia , 1984 .

[26]  T. Suda,et al.  Interferon regulatory factor-2 protects quiescent hematopoietic stem cells from type I interferon–dependent exhaustion , 2009, Nature Medicine.

[27]  J. Lipton,et al.  Phase II, randomized, multicenter, comparative study of peginterferon–α–2a (40 kD) (Pegasys®) versus interferon α-2a (Roferon®-A) in patients with treatment-naïve, chronic-phase chronic myelogenous leukemia , 2007 .

[28]  Susan O'Brien,et al.  Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Martin C. Müller,et al.  Erratum: Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia(Leukemia (2009) 23 (1054-1061) DOI: 10.1038/leu.2009.38) , 2010 .

[30]  Susan O'Brien,et al.  Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  T. Holyoake,et al.  Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. , 2002, Blood.

[32]  Jürg Zimmermann,et al.  Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.

[33]  G. Zon,et al.  Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. , 1995, Blood.

[34]  P. Saulnier,et al.  Interferon in chronic myeloid leukaemia: past and future. , 2009, Best practice & research. Clinical haematology.

[35]  Susan Branford,et al.  Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. , 2003, The New England journal of medicine.